BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...RNA sequences and recruit endogenous adenosine deaminase acting on RNA (ADAR) enzymes, which convert specific adenosine...
BioCentury | Jul 31, 2020
Distillery Therapeutics

ADORA2B agonism for obesity and aging-induced sarcopenia

...DISEASE CATEGORY: Endocrine/metabolic; musculoskeletal INDICATION: Obesity; musculoskeletal Promoting adenosine signaling through ADORA2B could treat obesity and...
...markers in aged mice. Ongoing work includes medicinal chemistry to develop novel ADORA2B agonists. TARGET/MARKER/PATHWAY: Adenosine...
...25, 2020 doi:10.1016/j.cmet.2020.06.006 CONTACT: Alexander Pfeifer, University of Bonn, Bonn, Germany email: alexander.pfeifer@uni-bonn.de Claire Quang University of Bonn Adenosine...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...C round last month that included crossover investors (see “Piling In” ). Targets ADORA2A - Adenosine...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...the receptor so that it can better inhibit ADORA2A activity in the presence of high adenosine...
...exchanges, the Hong Kong stock exchange and Shanghai’s STAR board. Targets ADORA2A (A2AR; ADORA2) - Adenosine...
BioCentury | Jun 24, 2020
Deals

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

...with Arcus Biosciences covers T cell checkpoint inhibitors and compounds that target immuno-metabolism via the adenosine...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

...rest of Arcus’ pipeline. Arcus’ pipeline includes anti-TIGIT mAb AB154; and two compounds targeting the adenosine...
...Access to Targets Ripe for Combination” ). TIGIT is a next-generation T cell checkpoint, whereas adenosine...
BioCentury | Jun 5, 2020
Deals

AstraZeneca adds RNA-modifying targets to oncology pipeline via Accent deal

...molecule against ADAR to treat solid tumors. ADAR is an RNA base editor that converts adenosine...
...with different aspects of RNA biology, including splicing and translational regulation. Targets ADAR (ADAR1) - Adenosine...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...microbiome-based therapeutics to treat cancer. Targets ADORA2A (A2AR; ADORA2) - Adenosine A2A receptor ADORA2B - Adenosine...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

...dual ADORA2A and ADORA2B antagonist AB928; and CD73-targeting small molecule AB680, which also targets the adenosine...
...Maintains Independence, Adds Firepower” ). Targets ADORA2A (A2AR; ADORA2) - Adenosine A2A receptor ADORA2B - Adenosine...
...Editor AB122 AB928 AB680 AB154 Gilead Sciences Inc. Arcus Biosciences Inc. T cell immunoreceptor with Ig and ITIM domains (TIGIT) Adenosine A2A receptor (ADORA2A) Adenosine...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...in 2018. The industry hasn’t given up on IDO, but attention is shifting to the adenosine...
...NSCLC ( No. e21659 ) Targets ADORA2A (A2AR; ADORA2) - Adenosine A2A receptor ADORA2B - Adenosine...
Items per page:
1 - 10 of 1110